首页 > 最新文献

Giornale italiano di cardiologia最新文献

英文 中文
[8th Census of Cardiology Centers in Italy]. [第八次意大利心脏病学中心普查]。
IF 0.5 Q4 Medicine Pub Date : 2024-02-01 DOI: 10.1714/4187.41753
Giuseppe Di Pasquale
{"title":"[8th Census of Cardiology Centers in Italy].","authors":"Giuseppe Di Pasquale","doi":"10.1714/4187.41753","DOIUrl":"10.1714/4187.41753","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Economic evaluation of a fixed-dose combination (acetylsalicylic acid and rosuvastatin) in the cardiovascular context]. [固定剂量组合(乙酰水杨酸和洛伐他汀)在心血管方面的经济评估]。
IF 0.5 Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1714/4182.41699
Sergio Di Matteo, Sabrin Moumene, Giorgio Lorenzo Colombo, Leonardo De Luca

Background: Cardiovascular diseases pose a significant challenge to the society and healthcare systems, with serious implications in terms of mortality and healthcare expenditure. The treatment of cardiovascular diseases, based on acetylsalicylic acid combined with statins in multi-pill regimens, is characterized by a lower adherence rate among patients compared to the single-pill combination. A potential solution lies in single-pill formulations, drugs that combine two or more active ingredients at a fixed dosage within the same dosage unit.

Methods: In order to assess the potential pharmacoeconomic impact of single-pill treatment, a budget impact model (BIM) was developed, considering the combination of 100 mg acetylsalicylic acid and 5 mg, 10 mg, or 20 mg rosuvastatin.

Results: The use of the single pill, according to the selected scenario, could result in savings in Italy compared to the use of multi-pill at 100%, ranging from € 951 201 in the case of using both single and multi-pill at 50%, to € 1 902 402 in the case of using the single pill exclusively. Sensitivity analysis confirmed the robustness of the results.

Conclusions: The developed BIM allows observing the potential savings that single-pill treatment could generate, linked both to an increase in adherence rates and the consequent improvement in clinical outcomes for patients, as well as the lower cost of medications. The use of single pills represents a promising solution to enhance patient adherence and reduce costs in the management of cardiovascular diseases in Italy.

背景:心血管疾病是社会和医疗系统面临的重大挑战,对死亡率和医疗支出造成严重影响。心血管疾病的治疗以乙酰水杨酸联合他汀类药物的多药方案为基础,与单药组合相比,患者的依从性较低。潜在的解决方案在于单丸制剂,即在同一剂量单位内以固定剂量组合两种或两种以上活性成分的药物:为了评估单药治疗的潜在药物经济学影响,我们建立了一个预算影响模型(BIM),考虑了 100 毫克乙酰水杨酸和 5 毫克、10 毫克或 20 毫克罗伐他汀的组合:结果:根据所选方案,与 100%使用多种药片相比,在意大利使用单一药片可节省费用 951 201 欧元(单一药片和多种药片各占 50%),而只使用单一药片则可节省 1 902 402 欧元。敏感性分析证实了结果的稳健性:通过所开发的 BIM,可以观察到单药丸治疗可能带来的潜在节约,这既与患者依从率的提高和随之而来的临床疗效的改善有关,也与药物成本的降低有关。在意大利,使用单一药片是提高患者依从性和降低心血管疾病治疗成本的一个很有前景的解决方案。
{"title":"[Economic evaluation of a fixed-dose combination (acetylsalicylic acid and rosuvastatin) in the cardiovascular context].","authors":"Sergio Di Matteo, Sabrin Moumene, Giorgio Lorenzo Colombo, Leonardo De Luca","doi":"10.1714/4182.41699","DOIUrl":"10.1714/4182.41699","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular diseases pose a significant challenge to the society and healthcare systems, with serious implications in terms of mortality and healthcare expenditure. The treatment of cardiovascular diseases, based on acetylsalicylic acid combined with statins in multi-pill regimens, is characterized by a lower adherence rate among patients compared to the single-pill combination. A potential solution lies in single-pill formulations, drugs that combine two or more active ingredients at a fixed dosage within the same dosage unit.</p><p><strong>Methods: </strong>In order to assess the potential pharmacoeconomic impact of single-pill treatment, a budget impact model (BIM) was developed, considering the combination of 100 mg acetylsalicylic acid and 5 mg, 10 mg, or 20 mg rosuvastatin.</p><p><strong>Results: </strong>The use of the single pill, according to the selected scenario, could result in savings in Italy compared to the use of multi-pill at 100%, ranging from € 951 201 in the case of using both single and multi-pill at 50%, to € 1 902 402 in the case of using the single pill exclusively. Sensitivity analysis confirmed the robustness of the results.</p><p><strong>Conclusions: </strong>The developed BIM allows observing the potential savings that single-pill treatment could generate, linked both to an increase in adherence rates and the consequent improvement in clinical outcomes for patients, as well as the lower cost of medications. The use of single pills represents a promising solution to enhance patient adherence and reduce costs in the management of cardiovascular diseases in Italy.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes]. [2023年ESC心内膜炎治疗指南]。
IF 0.5 Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1714/4162.41558
Nikolaus Marx, Massimo Federici, Katharina Schütt, Dirk Müller-Wieland, Carolyn Crawford, Björn Eliasson, Christine Espinola-Klein, Laurent Fauchier, Martin Halle, Alexandra Kautzky-Willer, Ekaterini Lambrinou, Maciej Lesiak, Maddalena Lettino, Wilfried Mullens, Bianca Rocca, Naveed Sattar
{"title":"[2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes].","authors":"Nikolaus Marx, Massimo Federici, Katharina Schütt, Dirk Müller-Wieland, Carolyn Crawford, Björn Eliasson, Christine Espinola-Klein, Laurent Fauchier, Martin Halle, Alexandra Kautzky-Willer, Ekaterini Lambrinou, Maciej Lesiak, Maddalena Lettino, Wilfried Mullens, Bianca Rocca, Naveed Sattar","doi":"10.1714/4162.41558","DOIUrl":"10.1714/4162.41558","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138884797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The economic assessment of the drug and the budget impact analysis in the context of Health Technology Assessment]. [健康技术评估中的药物经济评估和预算影响分析]。
IF 0.5 Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1714/4182.41698
Giorgio Lorenzo Colombo
{"title":"[The economic assessment of the drug and the budget impact analysis in the context of Health Technology Assessment].","authors":"Giorgio Lorenzo Colombo","doi":"10.1714/4182.41698","DOIUrl":"10.1714/4182.41698","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[2023 ESC Guidelines for the management of endocarditis]. [2023年ESC心内膜炎治疗指南]。
IF 0.5 Q4 Medicine Pub Date : 2023-12-01 DOI: 10.1714/4144.41413
Nina Ajmone Marsan, Suzanne de Waha, Nikolaos Bonaros, Margarita Brida, Haran Burri, Stefano Caselli, Torsten Doenst, Stephane Ederhy, Paola Anna Erba, Dan Foldager, Emil L Fosbø, Jan Kovac, Carlos A Mestres, Owen I Miller, Jose M Miro, Michal Pazdernik, Maria Nazarena Pizzi, Eduard Quintana, Trine Bernholdt Rasmussen, Arsen D Ristić, Josep Rodés-Cabau, Alessandro Sionis, Liesl Joanna Zühlke, Victoria Delgado, Michael A Borger
{"title":"[2023 ESC Guidelines for the management of endocarditis].","authors":"Nina Ajmone Marsan, Suzanne de Waha, Nikolaos Bonaros, Margarita Brida, Haran Burri, Stefano Caselli, Torsten Doenst, Stephane Ederhy, Paola Anna Erba, Dan Foldager, Emil L Fosbø, Jan Kovac, Carlos A Mestres, Owen I Miller, Jose M Miro, Michal Pazdernik, Maria Nazarena Pizzi, Eduard Quintana, Trine Bernholdt Rasmussen, Arsen D Ristić, Josep Rodés-Cabau, Alessandro Sionis, Liesl Joanna Zühlke, Victoria Delgado, Michael A Borger","doi":"10.1714/4144.41413","DOIUrl":"10.1714/4144.41413","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138884796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Empagliflozin: current indications and aspects for daily clinical practice]. [Empagliflozin: 当前适应症和日常临床实践方面]。
IF 0.5 Q4 Medicine Pub Date : 2023-12-01 DOI: 10.1714/4181.41696
Massimo Iacoviello, Nadia Aspromonte

Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The "serendipity" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.

Empagliflozin 属于钠-葡萄糖共转运体 2 抑制剂,可抑制近端肾曲小管对钠和葡萄糖的重吸收。empagliflozin的 "偶然性 "是基于其对糖尿病患者以及受心力衰竭和/或慢性肾病影响的患者(无论是否患有糖尿病)出乎意料的有益作用。本综述旨在全面更新有关安格列酮治疗心力衰竭的证据,并为日常临床实践提供有用的工具。
{"title":"[Empagliflozin: current indications and aspects for daily clinical practice].","authors":"Massimo Iacoviello, Nadia Aspromonte","doi":"10.1714/4181.41696","DOIUrl":"10.1714/4181.41696","url":null,"abstract":"<p><p>Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The \"serendipity\" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139471958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[2023 ESC Guidelines for the management of cardiomyopathies]. [2023 ESC心肌病管理指南]。
IF 0.5 Q4 Medicine Pub Date : 2023-11-01 DOI: 10.1714/4127.41209
Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R Bezzina, Elena Biagini, Nico A Blom, Rudolf A de Boer, Tim De Winter, Perry M Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H Haugaa, Jodie Ingles, Ruxandra Oana Jurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, Iacopo Olivotto, Antonis Pantazis, Sanjay Sharma, J Peter Van Tintelen, James S Ware, Juan Pablo Kaski
{"title":"[2023 ESC Guidelines for the management of cardiomyopathies].","authors":"Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R Bezzina, Elena Biagini, Nico A Blom, Rudolf A de Boer, Tim De Winter, Perry M Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H Haugaa, Jodie Ingles, Ruxandra Oana Jurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, Iacopo Olivotto, Antonis Pantazis, Sanjay Sharma, J Peter Van Tintelen, James S Ware, Juan Pablo Kaski","doi":"10.1714/4127.41209","DOIUrl":"10.1714/4127.41209","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The STEP-HFpEF trial: proof of concept that phenotypic therapy in heart failure with preserved ejection fraction can really be a valid therapeutic solution?] 【STEP HFpEF试验:射血分数保留的心力衰竭表型治疗是否真的是一种有效的治疗方案?】
IF 0.5 Q4 Medicine Pub Date : 2023-11-01 DOI: 10.1714/4129.41226
Michele Senni, Edoardo Sciatti
{"title":"[The STEP-HFpEF trial: proof of concept that phenotypic therapy in heart failure with preserved ejection fraction can really be a valid therapeutic solution?]","authors":"Michele Senni,&nbsp;Edoardo Sciatti","doi":"10.1714/4129.41226","DOIUrl":"10.1714/4129.41226","url":null,"abstract":"","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ANMCO Position paper: Ionizing radiation exposure and radioprotection in the cath-lab]. [ANMCO立场文件:阴极实验室的电离辐射暴露和辐射防护]。
IF 0.5 Q4 Medicine Pub Date : 2023-11-01 DOI: 10.1714/4129.41234
Fabiana Lucà, Maria Grazia Andreassi, Michele Massimo Gulizia, Andrea Borghini, Paola Enrica Colombo, Francesco Antonio Benedetto, Chiara Bernelli, Irma Bisceglia, Giovanni Bisignani, Pasquale Caldarola, Maria Laura Canale, Roberto Caporale, Giorgio Caretta, Roberto Ceravolo, Vincenzo Antonio Ciconte, Marco Corda, Stefano Cornara, Silvana De Bonis, Leonardo De Luca, Stefania Angela Di Fusco, Irene Di Matteo, Concetta Di Nora, Silvia Favilli, Sandro Gelsomino, Giovanna Geraci, Simona Giubilato, Andrea Matteucci, Federico Nardi, Alessandro Navazio, Iris Parrini, Annarita Pilleri, Andrea Pozzi, Carmelo Massimiliano Rao, Carmine Riccio, Roberta Rossini, Fabio Maria Turazza, Massimo Grimaldi, Domenico Gabrielli, Eugenio Picano, Furio Colivicchi, Fabrizio Oliva

In the last decades, because of the improvements in the percutaneous treatment of coronary heart disease, valvular heart disease, congenital heart defects, and the increasing number of cardiac resynchronization therapy and cardioverter-defibrillator implantations, the interventional cardiologists' radio-exposure has importantly risen, causing concerns for ionizing radiation-associated diseases such as cancer and neurodegenerative disorders. Consequently, the radiation exposure issue importantly affects operators' safety. However, our knowledge of this field is poor and most operators are unaware to be at risk, especially because of the absence of effective preventive measures. The aim of this ANMCO position paper is to improve the awareness of operators and identify new ways of reducing operator ionizing radiation dose and minimizing the risk.

在过去的几十年里,由于冠心病、瓣膜性心脏病、先天性心脏缺陷的经皮治疗的改进,以及心脏再同步治疗和心律转复除颤器植入的数量不断增加,介入心脏病专家的无线电暴露量显著增加,引起对电离辐射相关疾病如癌症和神经退行性疾病的关注。因此,辐射暴露问题严重影响了操作人员的安全。然而,我们对这一领域的了解很差,大多数运营商都不知道自己有风险,尤其是因为缺乏有效的预防措施。本ANMCO立场文件的目的是提高操作员的意识,并确定降低操作员电离辐射剂量和将风险降至最低的新方法。
{"title":"[ANMCO Position paper: Ionizing radiation exposure and radioprotection in the cath-lab].","authors":"Fabiana Lucà,&nbsp;Maria Grazia Andreassi,&nbsp;Michele Massimo Gulizia,&nbsp;Andrea Borghini,&nbsp;Paola Enrica Colombo,&nbsp;Francesco Antonio Benedetto,&nbsp;Chiara Bernelli,&nbsp;Irma Bisceglia,&nbsp;Giovanni Bisignani,&nbsp;Pasquale Caldarola,&nbsp;Maria Laura Canale,&nbsp;Roberto Caporale,&nbsp;Giorgio Caretta,&nbsp;Roberto Ceravolo,&nbsp;Vincenzo Antonio Ciconte,&nbsp;Marco Corda,&nbsp;Stefano Cornara,&nbsp;Silvana De Bonis,&nbsp;Leonardo De Luca,&nbsp;Stefania Angela Di Fusco,&nbsp;Irene Di Matteo,&nbsp;Concetta Di Nora,&nbsp;Silvia Favilli,&nbsp;Sandro Gelsomino,&nbsp;Giovanna Geraci,&nbsp;Simona Giubilato,&nbsp;Andrea Matteucci,&nbsp;Federico Nardi,&nbsp;Alessandro Navazio,&nbsp;Iris Parrini,&nbsp;Annarita Pilleri,&nbsp;Andrea Pozzi,&nbsp;Carmelo Massimiliano Rao,&nbsp;Carmine Riccio,&nbsp;Roberta Rossini,&nbsp;Fabio Maria Turazza,&nbsp;Massimo Grimaldi,&nbsp;Domenico Gabrielli,&nbsp;Eugenio Picano,&nbsp;Furio Colivicchi,&nbsp;Fabrizio Oliva","doi":"10.1714/4129.41234","DOIUrl":"https://doi.org/10.1714/4129.41234","url":null,"abstract":"<p><p>In the last decades, because of the improvements in the percutaneous treatment of coronary heart disease, valvular heart disease, congenital heart defects, and the increasing number of cardiac resynchronization therapy and cardioverter-defibrillator implantations, the interventional cardiologists' radio-exposure has importantly risen, causing concerns for ionizing radiation-associated diseases such as cancer and neurodegenerative disorders. Consequently, the radiation exposure issue importantly affects operators' safety. However, our knowledge of this field is poor and most operators are unaware to be at risk, especially because of the absence of effective preventive measures. The aim of this ANMCO position paper is to improve the awareness of operators and identify new ways of reducing operator ionizing radiation dose and minimizing the risk.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of postoperative arrhythmias in the tetralogy of Fallot: a literature review]. [法洛四联症术后心律失常的处理:文献综述]。
IF 0.5 Q4 Medicine Pub Date : 2023-11-01 DOI: 10.1714/4129.41232
Massimo Zoni Berisso, Fabrizio Drago, Alberto Battaglia, Elisabetta Mariucci, Gianluca Mirizzi, Gabriele Vignati, Berardo Sarubbi

Tetralogy of Fallot (ToF) occurs in about 4 births/1000/year and represents about one tenth of all congenital heart diseases. Nowadays 86% of patients reach adulthood with corrective surgery. Before the 1980s, these patients were treated only with "surgical palliation", which consisted in the creation of a systemic to pulmonary artery shunt or a pulmonary valvulotomy, whereas after the introduction of extracorporeal circulation, corrective surgery is performed electively between 3 and 6 months of life. After repair patients during their life may develop hemodynamic lesions, including right ventricular outflow tract dysfunction, and arrhythmias which can occur in over 30% of cases. It is estimated that these patients present a risk of sudden death of 0.2%/year. Therefore, for the prevention and treatment of arrhythmic events, a periodic follow-up in specialized centres for adult congenital heart disease is mandatory, because most often arrhythmias are triggered by the presence of hemodynamic lesions, first of all pulmonary regurgitation.

法洛四联症(ToF)发生在大约4个新生儿/1000年,约占所有先天性心脏病的十分之一。如今,86%的患者通过矫正手术达到成年。在20世纪80年代之前,这些患者只接受“手术缓解”治疗,即建立系统性肺动脉分流或肺瓣膜切开术,而在引入体外循环后,在3至6个月的生命中选择性地进行矫正手术。修复后,患者一生中可能会出现血液动力学损伤,包括右心室流出道功能障碍和心律失常,超过30%的病例会出现心律失常。据估计,这些患者每年有0.2%的猝死风险。因此,为了预防和治疗心律失常事件,必须在成人先天性心脏病专科中心进行定期随访,因为心律失常通常是由血液动力学损伤引发的,首先是肺反流。
{"title":"[Management of postoperative arrhythmias in the tetralogy of Fallot: a literature review].","authors":"Massimo Zoni Berisso,&nbsp;Fabrizio Drago,&nbsp;Alberto Battaglia,&nbsp;Elisabetta Mariucci,&nbsp;Gianluca Mirizzi,&nbsp;Gabriele Vignati,&nbsp;Berardo Sarubbi","doi":"10.1714/4129.41232","DOIUrl":"https://doi.org/10.1714/4129.41232","url":null,"abstract":"<p><p>Tetralogy of Fallot (ToF) occurs in about 4 births/1000/year and represents about one tenth of all congenital heart diseases. Nowadays 86% of patients reach adulthood with corrective surgery. Before the 1980s, these patients were treated only with \"surgical palliation\", which consisted in the creation of a systemic to pulmonary artery shunt or a pulmonary valvulotomy, whereas after the introduction of extracorporeal circulation, corrective surgery is performed electively between 3 and 6 months of life. After repair patients during their life may develop hemodynamic lesions, including right ventricular outflow tract dysfunction, and arrhythmias which can occur in over 30% of cases. It is estimated that these patients present a risk of sudden death of 0.2%/year. Therefore, for the prevention and treatment of arrhythmic events, a periodic follow-up in specialized centres for adult congenital heart disease is mandatory, because most often arrhythmias are triggered by the presence of hemodynamic lesions, first of all pulmonary regurgitation.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71411589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Giornale italiano di cardiologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1